About: Kiat Ruxrungtham

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Kiat Ruxrungtham Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Professor of Medicine

Attributes	Values
rdf:type	Item
description	Professor of Medicine (en) ศาสตราจารย์ นายแพทย์ (th)
rdfs:label	Kiat Ruxrungtham (en) Kiat Ruxrungtham (nl) Kiat Ruxrungtham (ast) เกียรติ รักษ์รุ่งธรรม (th)
skos:prefLabel	Kiat Ruxrungtham (en) Kiat Ruxrungtham (nl) Kiat Ruxrungtham (ast) เกียรติ รักษ์รุ่งธรรม (th)
name	Kiat Ruxrungtham (en) Kiat Ruxrungtham (nl) Kiat Ruxrungtham (ast) เกียรติ รักษ์รุ่งธรรม (th)
Scopus author ID	wds:Q66733145-ca85f076-4a17-2fbc-a7ff-142c987f5192
Scopus author ID	7004208798
instance of	wds:Q66733145-898C3B15-5F61-465E-9545-5984731B6DE6
instance of	Homo sapiens
VIAF ID	wds:Q66733145-2AA275D0-1983-419F-9055-6024CE855ECD
IdRef ID	wds:Q66733145-97CBF48B-F7B0-4901-84AE-A863B8DCDD46
WorldCat Identities ID (superseded)	wds:Q66733145-E5FC0779-3FA2-4598-9E08-3633B56F62A1
VIAF ID	http://viaf.org/viaf/283955444
IdRef ID	http://www.idref.fr/164327444/id
VIAF ID	283955444
IdRef ID	164327444
WorldCat Identities ID (superseded)	viaf-283955444
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q66733145
is author of	CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Treatment of HIV infection with once-daily regimens Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients Plasma levels of soluble CD14 independently predict mortality in HIV infection Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand HIV/AIDS in Asia Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in Thai patients Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in Bangkok A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais Impact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT study A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting. Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality Prevalence of anemia and underlying iron status in naive antiretroviral therapy HIV-infected children with moderate immune suppression Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 Lessons from a multicentre paediatric HIV trial HIV drug resistance transmission threshold survey in Bangkok, Thailand.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software